Pharmacological, neural, and psychological mechanisms underlying psychedelics: a critical review
Michiel van Elk, David Bryce Yaden
Neuroscience & Biobehavioral Reviews September 1, 2022 DOI: 10.1016/j.neubiorev.2022.104793 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Intervention | Psychedelics |
| Keywords | Psychedelics Compounds Hallucinogens Entheogens Psychotropics Mental health therapy Innovative treatments Psychotherapy Psychiatric treatment Well-being Psychological health Brain function Neural circuits Neurobiology Cognitive science Neurology Consciousness Perception Awareness Mind Subjective experience Cognition Mood |
| Citations | 214 |
| Key findings | Psychedelics operate through multiple mechanisms across biochemical, neural, and psychological levels, and a better understanding of these pathways could enable more targeted therapeutic approaches. |
Abstract
This paper provides a critical review of several possible mechanisms at different levels of analysis underlying the effects and therapeutic potential of psychedelics. At the (1) biochemical level, psychedelics primarily affect the 5-HT2A receptor, increase neuroplasticity, offer a critical period for social reward learning, and have anti-inflammatory properties. At the (2) neural level, psychedelics have been associated with reduced efficacy of thalamo-cortical filtering, the loosening of top-down predictive signaling and an increased sensitivity to bottom-up prediction errors, and activation of the claustro-cortical-circuit. At the (3) psychological level, psychedelics have been shown to induce altered and affective states, they affect cognition, induce belief change, exert social effects, and can result in lasting changes in behavior. We outline the potential for a unifying account of the mechanisms underlying psychedelics and contrast this with a model of pluralistic causation. Ultimately, a better understanding of the specific mechanisms underlying the effects of psychedelics could allow for a more targeted therapeutic approach. We highlight current challenges for psychedelic research and provide a research agenda to foster insight in the causal-mechanistic pathways underlying the efficacy of psychedelic research and therapy.
Citations in the library
Cited by 180
- Treatment of Posttraumatic Stress Disorder: A State-of-the-art Review. Current Neuropharmacology 2024
- Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study Nature Medicine July 24, 2023
- History repeating: guidelines to address common problems in psychedelic science Therapeutic Advances in Psychopharmacology 2023
- Therapeutic effect of psilocybin in addiction: A systematic review Frontiers in Psychiatry February 9, 2023
- Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study Brain, Behavior, and Immunity September 7, 2023
and 175 more in the library
Cites 156
- The Brain's Default Mode Network Annual Review of Neuroscience May 4, 2015
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
and 151 more in the library